ABSTRACT Loads of medications and vaccines are under investigation to prevent and heal coronavirus disease 2019 (COVID-19), which is putting a strain on healthcare systems worldwide. Among them, therapy with neutralizing monoclonal antibodies (nAbs) seems to be very promising in halting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the illness and in providing the patients with passive immunity. NAbs are designed to mimic the body’s natural immune response. Coronavirus infection is mediated by the interplay between the viral spike and the tissue angiotensin-converting enzyme 2 (ACE 2) receptor found on the apical surface of numerous cell types. However, nAbs are capable of blocking this interaction. They bind to the spike protein, thus impeding SARS-CoV-2 to enter human cells and tagging it for destruction. NAbs can be crucial in preventing COVID-19 from progressing to a severe form, and potentially are a prophylaxis option to subjects who have been exposed to SARS-CoV-2, while still waiting to get a vaccine. This mini review provides the readers with an overview about what is already known and what is new about the use of these agents.
View Full Article
|